Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory agent classified as an antineoplastic, presented as a tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic marrow.

- Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle Cell Lymphoma: provides disease control in relapsed or refractory adult patients.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: mild to moderate tiredness. - Diarrhea: loose, sometimes watery stools. - Rash: skin erythema or pruritus. - Neutropenia: reduced neutrophil count, increasing infection risk.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers during therapy.

Lenalidomide requires careful monitoring and specific safety measures.

- Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thrombosis monitoring: assess for signs of blood clots and consider prophylaxis. - Hematologic monitoring: regular CBC to detect neutropenia, anemia, and thrombocytopenia. - Renal function: evaluate and adjust use in patients with impaired renal clearance. - Drug interactions: avoid concomitant use with strong CYP inducers without supervision. - Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Lenalidomide can interact with several drug classes; some combinations should be avoided while others require close observation.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin) combined without monitoring: increased risk of bleeding.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma concentrations. - CYP3A4 inhibitors (e.g., ketoconazole): can modestly increase exposure. - Live attenuated vaccines: may have reduced efficacy; avoid during therapy.